MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

CF Bronchodilation

Not Applicable
Active, not recruiting
Conditions
Lung Diseases
Cystic Fibrosis
Interventions
Drug: Salbutamol
Drug: Placebo
First Posted Date
2018-05-11
Last Posted Date
2023-12-14
Lead Sponsor
University of British Columbia
Target Recruit Count
20
Registration Number
NCT03522831
Locations
🇨🇦

UBC Cardiopulmonary Exercise Physiology Laboratory, Vancouver, British Columbia, Canada

Status Asthmaticus on the PICU; Intravenous Salbutamol

Phase 4
Completed
Conditions
Childhood Asthma With Status Asthmaticus
Interventions
First Posted Date
2018-04-10
Last Posted Date
2020-07-30
Lead Sponsor
Erasmus Medical Center
Target Recruit Count
58
Registration Number
NCT03493503
Locations
🇳🇱

Erasmus MC, Rotterdam, Zuid-Holland, Netherlands

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Phase 3
Completed
Conditions
Asthma, Allergic
Interventions
First Posted Date
2018-03-19
Last Posted Date
2021-10-11
Lead Sponsor
Shanghai Biomabs Pharmaceutical Co., Ltd.
Target Recruit Count
393
Registration Number
NCT03468790
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

🇨🇳

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Phase 3
Conditions
Chronic Obstructive Pulmonary Disease
High-flow Nasal Cannula
Interventions
First Posted Date
2018-02-28
Last Posted Date
2019-02-12
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
25
Registration Number
NCT03449056
Locations
🇫🇷

C.H.U. de Poitiers, Poitiers, France

Effects of Noninvasive Ventilation Compared to Salbutamol

Not Applicable
Completed
Conditions
Asthma
Interventions
Device: Bilevel
Drug: Albuterol
First Posted Date
2018-02-13
Last Posted Date
2019-07-22
Lead Sponsor
University of Nove de Julho
Target Recruit Count
30
Registration Number
NCT03430505
Locations
🇧🇷

Nove de Julho University, São Paulo, Brazil

Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators

Phase 4
Completed
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2018-01-19
Last Posted Date
2024-04-03
Lead Sponsor
Dr. Denis O'Donnell
Target Recruit Count
20
Registration Number
NCT03405090
Locations
🇨🇦

Respiratory Investigation Unit, Kingston, Ontario, Canada

A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects

Phase 4
Completed
Conditions
Asthma
Interventions
Drug: RELVAR/BREO
Drug: Salbutamol
Device: Smart phone app
Device: HCP Dashboard
Device: Sensors
First Posted Date
2017-12-21
Last Posted Date
2021-04-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
437
Registration Number
NCT03380429
Locations
🇬🇧

GSK Investigational Site, Harrogate, United Kingdom

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
First Posted Date
2017-12-13
Last Posted Date
2019-07-23
Lead Sponsor
AstraZeneca
Target Recruit Count
46
Registration Number
NCT03371459
Locations
🇺🇸

Research Site, Medford, Oregon, United States

Sensor and Electronic Health Records (EHR) Integration Pilot Study

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Device: Mobile spirometer
Device: Device sensor
Drug: Salbutamol
Device: Activity monitor
Other: ACT
Other: electronic diary card
Other: CAT
First Posted Date
2017-11-29
Last Posted Date
2020-11-24
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
194
Registration Number
NCT03357341
Locations
🇺🇸

GSK Investigational Site, Danville, Pennsylvania, United States

Effect of Inhaled Albuterol in Pulmonary Hypertension

Phase 2
Completed
Conditions
Pulmonary Hypertension
Interventions
Drug: Albuterol
Drug: Placebo
First Posted Date
2017-09-01
Last Posted Date
2021-08-30
Lead Sponsor
University of Miami
Target Recruit Count
10
Registration Number
NCT03270332
Locations
🇺🇸

University of Miami, Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath